Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

1.3K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.3K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

860
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
860
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

508
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
508
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

972
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
972
Bacterial Flora of the Large Intestine01:29

Bacterial Flora of the Large Intestine

1.8K
The gut microbiome is formed by a vast and diverse community of bacteria that colonizes our large intestine. These bacteria start residing in the gut from birth and continue diversifying throughout life, influenced by factors such as diet, lifestyle, and stress. The gut bacterial community also includes bacteria from food and those that enter the colon through the anus.
The normal gut flora of the colon plays a critical role in generating essential vitamins such as vitamins K, B5, and B7.
1.8K
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

798
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
798

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Microplastics as emerging viral vectors: Nexus, mechanisms, ecological implications and health risks.

Environmental research·2026
Same author

Corrigendum to "Targeting Staphylococcus aureus with potent de novo-designed proline-core short antimicrobial lipopeptides" [Eur. J. Med. Chem. 310 (2026) 118784].

European journal of medicinal chemistry·2026
Same author

Feasibility Assessment of Telehealth-Based Cancer Pain Management Through Machine Learning: A Prospective Clinical Study.

Pain research & management·2026
Same author

Driving HCV Elimination Through Dedicated Hospital-Based Teams and Pathways: A Retrospective and Prospective Study.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Micro- and Nanoplastics as Disruptors of Digestive and Hepatopancreatic Homeostasis: Insights into the Plastic-Gut-Liver Axis.

International journal of molecular sciences·2026
Same author

Correction: De Caro et al. Optimizing Textile Disinfection in Hospital-Associated Infections Using Gaseous Ozone. <i>Pathogens</i> 2025, <i>14</i>, 977.

Pathogens (Basel, Switzerland)·2026

Related Experiment Video

Updated: Feb 28, 2026

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.5K

Emerging Therapeutic Approaches for Modulating the Intestinal Microbiota.

Ilaria Cosimato1, Annalisa Brescia2, Gianluigi Franci1,3

  • 1Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, 84081 Baronissi, Italy.

Pharmaceutics
|February 27, 2026
PubMed
Summary

Emerging therapies like fecal microbiota transplantation (FMT) and phage therapy show promise for restoring gut microbial balance (eubiosis) and treating diseases linked to dysbiosis. Further research is needed for safety and standardization.

Keywords:
BCTFMTOMVsdysbiosismicrobiotatherapeutics

More Related Videos

An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota
07:15

An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota

Published on: July 31, 2019

10.5K
A Novel Method for the Culture and Polarized Stimulation of Human Intestinal Mucosa Explants
06:38

A Novel Method for the Culture and Polarized Stimulation of Human Intestinal Mucosa Explants

Published on: May 1, 2013

13.6K

Related Experiment Videos

Last Updated: Feb 28, 2026

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.5K
An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota
07:15

An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota

Published on: July 31, 2019

10.5K
A Novel Method for the Culture and Polarized Stimulation of Human Intestinal Mucosa Explants
06:38

A Novel Method for the Culture and Polarized Stimulation of Human Intestinal Mucosa Explants

Published on: May 1, 2013

13.6K

Area of Science:

  • Microbiology
  • Gastroenterology
  • Immunology

Background:

  • The gut microbiota significantly impacts host metabolism, immunity, and disease.
  • Microbial imbalance (dysbiosis) is linked to gastrointestinal and extraintestinal conditions.
  • Restoring microbial balance (eubiosis) is crucial for human health.

Purpose of the Study:

  • To review emerging therapeutic strategies for modulating the gut microbiota.
  • To explore novel approaches for treating microbiota-associated diseases.

Main Methods:

  • Narrative review of preclinical and clinical studies.
  • Focus on fecal microbiota transplantation (FMT), bacterial consortium transplantation (BCT), phage therapy, and outer membrane vesicles (OMVs).

Main Results:

  • Probiotics, prebiotics, and synbiotics show potential but are context-dependent.
  • FMT is effective for recurrent Clostridioides difficile infections and being studied for other conditions.
  • BCT, phage therapy, and OMVs are emerging strategies with early promising results.

Conclusions:

  • Novel gut microbiota modulation strategies offer new avenues for precision medicine.
  • These therapies could revolutionize disease prevention and treatment.
  • Further research is essential to ensure safety, standardization, and clinical applicability.